Teva shares jump by 26% on Wall Street as its most promising drug shows exceptional trial results

Duvakitug, a treatment for colitis and Crohn’s disease, surpassed expectations and positions Teva to compete in the $28 billion global inflammatory bowel disease market       | Read More ynet – Business